September JAAD: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phas
AAD's Dialogues in Dermatology - Un pódcast de American Academy of Dermatology
Andrew Blauvelt, MD, FAAD interviewed by Jackie Dosal, MD, FAAD
